NEUROGESX
NeurogesX, Inc., a biopharmaceutical company, engages in the development and commercialization of novel pain management therapies. It primarily focuses on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP), and painful diabetic neuropathy (PDN). The company's lead product candidate NGX-4010 is a dermal patch containing capsaicin, a selective TRPV1 agonist designed to manage pain associated with peripheral neuropathic p... ain conditions. It is also developing NGX-1998, a non-patch liquid formulation of synthetic capsaicin, and an opioid analgesic for use in managing pain associated with other chronic pain conditions, such as cancer pain. The company was founded in 1998 as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in 2000. NeurogesX is headquartered in San Mateo, California.
NEUROGESX
Industry:
Biotechnology Medical Medical Device Neuroscience
Founded:
1998-01-01
Address:
San Carlos, California, United States
Country:
United States
Website Url:
http://www.neurogesx.com
Total Employee:
11+
Status:
Active
Contact:
16503198757
Email Addresses:
[email protected]
Total Funding:
135.44 M USD
Technology used in webpage:
Confluence Networks Data Foundry
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
SV Health Investors
SV Health Investors investment in Post-IPO Equity - NeurogesX
Alta Partners
Alta Partners investment in Series D - NeurogesX
ARCH Venture Partners
ARCH Venture Partners investment in Series D - NeurogesX
Mitsubishi International Corporation (MIC)
Mitsubishi International Corporation (MIC) investment in Series D - NeurogesX
Global Life Science Ventures
Global Life Science Ventures investment in Series D - NeurogesX
Walden International
Walden International investment in Series D - NeurogesX
Montreux Equity Partners
Montreux Equity Partners investment in Series D - NeurogesX
University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill investment in Series C - NeurogesX
Diamond Capital Management
Diamond Capital Management investment in Series C - NeurogesX
ARCH Venture Partners
ARCH Venture Partners investment in Series C - NeurogesX
Official Site Inspections
http://www.neurogesx.com Semrush global rank: 5.76 M Semrush visits lastest month: 536
- Host name: acf3b736b777428f5.awsglobalaccelerator.com
- IP address: 15.197.240.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "NeurogesX"
NeurogesX - Crunchbase Company Profile & Funding
NeurogesX, Inc., a biopharmaceutical company, engages in the development and commercialization of novel pain management therapies. It primarily focuses on chronic …See details»
Neurogesx, Inc. Company Profile | San Mateo, CA | Competitors ...
Company Description: NeurogesX is paving the way for treating neuropathic pain, or chronic pain caused by damaged nerves. The company's lead candidate is Qutenza (formerly known as …See details»
NeurogesX Company Profile 2024: Valuation, Investors …
Where is NeurogesX headquartered? NeurogesX is headquartered in Foster City, CA. What is the size of NeurogesX? NeurogesX has 35 total employees. What …See details»
NeurogesX Inc - Company Profile and News - Bloomberg Markets
NeurogesX, Inc. is a biopharmaceutical company. The Company develops treatments for chronic peripheral neuropathic pain including postherpetic neuralgia, painful HIV-distal sensory...See details»
Neurogesx - Products, Competitors, Financials, Employees, …
NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including …See details»
NeurogesX - Overview, News & Similar companies | ZoomInfo.com
May 3, 2023 · NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain …See details»
NeurogesX - Funding, Financials, Valuation & Investors - Crunchbase
NeurogesX develops and commercializes therapies for chronic peripheral neuropathic pain.See details»
NeurogesX - Contacts, Employees, Board Members, Advisors
NeurogesX develops and commercializes therapies for chronic peripheral neuropathic pain.See details»
NeurogesX, Inc. | Insights
Jan 11, 2017 · Acorda Therapeutics paid NeurogesX $7.9 million up front for a commercial pain therapy and a late-stage, topical pain drug candidate – from which Acorda expects to derive …See details»
FDA Supports Phase 3 Trial for NGX-1998
Aug 20, 2012 · NeurogesX Inc., a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, provided an …See details»
NeurogesX, Inc. (NGSX) President and Chief Executive ... - Nasdaq, …
Apr 5, 2010 · For further information, please visit the company's website at: http://www.neurogesx.com. About NASDAQ OMX: The NASDAQ OMX Group, Inc. is the …See details»
NeurogesX, Inc. Inks Deal with Astellas Pharma Inc. for Back
Jun 22, 2009 · NeurogesX will receive EUR 30 million (approximately $42 million) for Qutenza commercialization rights, and EUR 5 million (approximately $7 million) for a license option of …See details»
Acorda Therapeutics acquires NeurogesX - 2013-04-15 - Crunchbase
Apr 15, 2013 · MarketScreener — Acorda Therapeutics, Inc. completed the acquisition of substantially all assets of NeurogesX, Inc. for $12.4 million.See details»
NeurogesX, Inc. Expands Commercial Operations Leadership
Nov 5, 2009 · NeurogesX is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral …See details»
NeurogesX Receives FDA Orphan Drug Designation for …
Jun 3, 2009 · NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on …See details»
NeurogesX Careers and Employment | Indeed.com
Mar 28, 2013 · Find out what works well at NeurogesX from the people who know best. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Compare pay for popular …See details»
NeurogesX seeks partners for pain drugs | Reuters
April 17 (Reuters) - Pharmaceutical company NeurogesX Inc appointed advisory firm JSB-Partners to help find partners for its neuropathic pain drugs. The U.S. Food and Drug …See details»
NeurogesX Receives FDA Approval of Qutenza(TM ... - Fierce Biotech
Nov 17, 2009 · Qutenza delivers a synthetic form of capsaicin, the substance in chili peppers that gives them their heat sensation, through a dermal delivery system, providing up to 12 weeks of …See details»
NeurogesX - Crunchbase
NeurogesX develops and commercializes therapies for chronic peripheral neuropathic pain.See details»
Neurogesx (NGSX) Full Chart - The Globe and Mail
Customizable Interactive Stock Chart for Neurogesx showing Real-time Prices & Technical Studies. Compare Performance vs. Index Returns & more.See details»